FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140147891> ?p ?o ?g. }

• W2140147891 endingPage "6496" @default.
• W2140147891 startingPage "6485" @default.
• W2140147891 abstract "Abstract Purpose: The progressive immune dysfunctions that occur in patients with advanced melanoma make them unlikely to efficiently respond to cancer vaccines. A multicenter randomized phase II trial was conducted to test whether immunization with modified HLA class I tumor peptides in the context of adjuvant therapy results in better immunologic responses and improved clinical outcomes in patients with early melanoma (stages IIB/C-III). Experimental Design: Forty-three patients were enrolled to undergo vaccination (n = 22) or observation (n = 21). The vaccine included four HLA-A*0201–restricted modified peptides (Melan-A/MART-1[27L], gp100[210M], NY-ESO-1[165V], and Survivin[97M]) emulsified in Montanide ISA51 and injected subcutaneously in combination with cyclophosphamide (300 mg/m2) and low-dose IL-2 (3 × 106 IU). The immune responses were monitored using ex vivo IFN-γ–ELISpot, HLA/multimer staining, and in vitro short-term peptide sensitization assays. Results: Vaccination induced a rapid and persistent increase in specific effector memory CD8+ T cells in 75% of the patients. However, this immunization was not associated with any significant increase in disease-free or overall survival as compared with the observation group. An extensive immunologic analysis revealed a significantly reduced cross-recognition of the corresponding native peptides and, most importantly, a limited ability to react to melanoma cells. Conclusions: Adjuvant setting is an appealing approach for testing cancer vaccines because specific CD8+ T cells can be efficiently induced in most vaccinated patients. However, the marginal antitumor activity of the T cells induced by modified peptides in this study largely accounts for the observed lack of benefit of vaccination. These findings suggest reconsidering this immunization strategy, particularly in early disease. Clin Cancer Res; 18(23); 6485–96. ©2012 AACR." @default.
• W2140147891 created "2016-06-24" @default.
• W2140147891 creator A5001474540 @default.
• W2140147891 creator A5008685924 @default.
• W2140147891 creator A5009296036 @default.
• W2140147891 creator A5018481533 @default.
• W2140147891 creator A5018536695 @default.
• W2140147891 creator A5023762347 @default.
• W2140147891 creator A5024169397 @default.
• W2140147891 creator A5025541066 @default.
• W2140147891 creator A5031591368 @default.
• W2140147891 creator A5032620018 @default.
• W2140147891 creator A5032626281 @default.
• W2140147891 creator A5049297270 @default.
• W2140147891 creator A5058078884 @default.
• W2140147891 creator A5059818282 @default.
• W2140147891 creator A5061751736 @default.
• W2140147891 creator A5062210857 @default.
• W2140147891 creator A5062761216 @default.
• W2140147891 creator A5066838580 @default.
• W2140147891 creator A5067882748 @default.
• W2140147891 creator A5069765350 @default.
• W2140147891 creator A5071691136 @default.
• W2140147891 creator A5078661531 @default.
• W2140147891 creator A5085140427 @default.
• W2140147891 creator A5087113555 @default.
• W2140147891 date "2012-11-29" @default.
• W2140147891 modified "2023-09-27" @default.
• W2140147891 title "Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides" @default.
• W2140147891 cites W1519645049 @default.
• W2140147891 cites W1572267688 @default.
• W2140147891 cites W1599999513 @default.
• W2140147891 cites W1904833722 @default.
• W2140147891 cites W1928212615 @default.
• W2140147891 cites W1933510216 @default.
• W2140147891 cites W1964186644 @default.
• W2140147891 cites W1965416876 @default.
• W2140147891 cites W1973091654 @default.
• W2140147891 cites W1975543140 @default.
• W2140147891 cites W1984484036 @default.
• W2140147891 cites W1993659680 @default.
• W2140147891 cites W2002250199 @default.
• W2140147891 cites W2002706481 @default.
• W2140147891 cites W2004680217 @default.
• W2140147891 cites W2012148175 @default.
• W2140147891 cites W2017672874 @default.
• W2140147891 cites W2021046976 @default.
• W2140147891 cites W2034625094 @default.
• W2140147891 cites W2035862592 @default.
• W2140147891 cites W2069132539 @default.
• W2140147891 cites W2081710396 @default.
• W2140147891 cites W2089401318 @default.
• W2140147891 cites W2091116096 @default.
• W2140147891 cites W2099735866 @default.
• W2140147891 cites W2101553545 @default.
• W2140147891 cites W2103959341 @default.
• W2140147891 cites W2111468537 @default.
• W2140147891 cites W2115454016 @default.
• W2140147891 cites W2119077297 @default.
• W2140147891 cites W2123264723 @default.
• W2140147891 cites W2130185552 @default.
• W2140147891 cites W2131989349 @default.
• W2140147891 cites W2132562995 @default.
• W2140147891 cites W2132770291 @default.
• W2140147891 cites W2137605317 @default.
• W2140147891 cites W2139863489 @default.
• W2140147891 cites W2142959209 @default.
• W2140147891 cites W2146226600 @default.
• W2140147891 cites W2146437446 @default.
• W2140147891 cites W2147968481 @default.
• W2140147891 cites W2148226248 @default.
• W2140147891 cites W2161255301 @default.
• W2140147891 cites W2162771736 @default.
• W2140147891 doi "https://doi.org/10.1158/1078-0432.ccr-12-1516" @default.
• W2140147891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23032742" @default.
• W2140147891 hasPublicationYear "2012" @default.
• W2140147891 type Work @default.
• W2140147891 sameAs 2140147891 @default.
• W2140147891 citedByCount "65" @default.
• W2140147891 countsByYear W21401478912013 @default.
• W2140147891 countsByYear W21401478912014 @default.
• W2140147891 countsByYear W21401478912015 @default.
• W2140147891 countsByYear W21401478912016 @default.
• W2140147891 countsByYear W21401478912017 @default.
• W2140147891 countsByYear W21401478912018 @default.
• W2140147891 countsByYear W21401478912019 @default.
• W2140147891 countsByYear W21401478912020 @default.
• W2140147891 countsByYear W21401478912021 @default.
• W2140147891 countsByYear W21401478912022 @default.
• W2140147891 countsByYear W21401478912023 @default.
• W2140147891 crossrefType "journal-article" @default.
• W2140147891 hasAuthorship W2140147891A5001474540 @default.
• W2140147891 hasAuthorship W2140147891A5008685924 @default.
• W2140147891 hasAuthorship W2140147891A5009296036 @default.
• W2140147891 hasAuthorship W2140147891A5018481533 @default.
• W2140147891 hasAuthorship W2140147891A5018536695 @default.
• W2140147891 hasAuthorship W2140147891A5023762347 @default.
• W2140147891 hasAuthorship W2140147891A5024169397 @default.

• next